Key Highlights

  • Sonoma reported fiscal 2026 full-year Revenue of $19.5 million, up 37% year over year, with fourth-quarter revenue up 48%.
  • The company achieved its first-ever positive adjusted EBITDA alongside a per-share loss narrowing to about nine cents from 76 cents.
  • In June 2026, Sonoma received FDA 510(k) clearance expanding indications and packaging for its Microdacyn wound irrigation solution.

Sonoma Pharmaceuticals is a micro-cap with an outsized product footprint, selling stabilized hypochlorous acid therapies into dermatology, wound care, eye care and animal health across dozens of countries. After a stretch of accelerating revenue and its first taste of positive adjusted profitability, the stock, trading around $1.30 in early September 2026, slipped modestly in a recent session. For Sonoma Pharmaceuticals (NASDAQ: SNOA), the more important context is a fundamental turn that has been building for several quarters.

Company and Latest Development

Sonoma Pharmaceuticals, based in Boulder, Colorado, develops and manufactures products built on its stabilized hypochlorous acid technology, marketed under brands including Microcyn and Microdacyn for wound care and related indications. On June 16, 2026, the company reported fiscal 2026 results, for its fiscal year ended March 31, with full-year revenue of $19.5 million, up 37% year over year, and fourth-quarter revenue of $5.6 million, up 48%. U.S. sales were a particular standout, and management pointed to new partnerships and product clearances as growth drivers.

What Is Driving Attention Around SNOA?

The supplied headline frames SNOA as slipping and asks what is pressuring the stock. On the available evidence, the small daily decline does not tie to any single confirmed negative catalyst; as a micro-cap with a Market Value of only a few million dollars, SNOA can move sharply on light volume. The more durable narrative is improving fundamentals. In its most recent quarterly report, filed in August 2026, the company highlighted strong U.S. revenue growth and what it described as its first-ever positive adjusted EBITDA, alongside a sharply narrower per-share loss versus a year earlier.

Key Numbers and Company Position

For fiscal 2026, Sonoma reported $19.5 million in revenue, up 37%, with fourth-quarter revenue up 48% and gross Margin in the high-30s percent range. In its subsequent fiscal first quarter, the company reported roughly 60% total revenue growth and about 141% U.S. revenue growth, with a loss per share narrowing to about nine cents from 76 cents a year earlier, and its first-ever positive adjusted EBITDA. In June 2026, Sonoma received an FDA 510(k) clearance expanding indications and packaging for its Microdacyn wound irrigation solution. The stock trades on the Nasdaq with a market Capitalization near $6 million; shares were about $1.30 on September 9, 2026.

What Could Come Next?

Investors may watch whether Sonoma can sustain its U.S. growth and adjusted-EBITDA momentum into future quarters, and whether new retail and Partnership channels, including a burn-relief hydrogel launched into major U.S. retailers earlier in 2026, scale meaningfully. Additional regulatory clearances, geographic expansion and further distribution partnerships could act as catalysts. The next Quarterly Report will be an important checkpoint on whether the recent inflection proves durable.

Risks to Watch

As a micro-cap, SNOA carries pronounced Liquidity and Volatility risk, and its small revenue base makes results sensitive to individual partnerships and orders. Although adjusted EBITDA turned positive, the company has a long history of losses, and sustaining profitability is not guaranteed. Competition in wound care and consumer health is intense, and reliance on distribution partners introduces concentration risk. Currency exposure from international sales and the possibility of future capital needs are additional considerations.

Conclusion

Sonoma Pharmaceuticals has paired rapid U.S. revenue growth with its first positive adjusted EBITDA, a genuine inflection for a company long defined by losses. The recent dip in SNOA shares appears consistent with micro-cap trading dynamics rather than any confirmed setback. Investors following the stock may be watching whether revenue momentum and improving profitability persist, how new retail and partnership channels perform, and whether additional regulatory clearances broaden the reach of its hypochlorous acid product portfolio.